Skip to main content

September 2023 Vol 16, No 5

This section provides a brief overview of new cancer drugs and new indications approved by the FDA between August 9, 2023, and August 14, 2023. Read More ›

Alexandria, VA—In the Prevent Cancer Foundation’s first annual Early Detection Survey, 65% of Americans aged ≥21 years say they are not up to date with one or more routine cancer screenings. Read More ›
Prevent Cancer Foundation provides resources and tools for you to check your health and inspire action for better outcomes.

According to the American Cancer Society, approximately 288,300 men in the United States will be diagnosed with prostate cancer in 2023 and 34,700 deaths will be attributed to the disease. September is Prostate Cancer Awareness Month, a time designated to help people learn more about the disease and to support those who are affected. Read More ›
An interview with Shelby Moneer, MS, CHES, Vice President, Patient Programs and Education, ZERO Prostate Cancer, Alexandria, VA

Cancer clinical trials offer patients an opportunity to be treated with the most cutting-edge and promising therapies available, but the majority of patients who are offered these trials still are not signing up for them. Read More ›

Opioids such as morphine are the gold standard for treating cancer-induced bone pain, but new University of Arizona Health Sciences research recently published in PAIN uncovered a mechanism by which chronic morphine use may increase bone loss and pain. Read More ›

Generic medicines are the backbone of the US prescription drug market, supplying more than 9 out of every 10 prescriptions. And the production of generic medicines overall has been remarkably stable—even during challenges such as the COVID-19 pandemic. Read More ›

Cancer researchers continue to make progress in developing tests using liquid biopsies that could complement and even serve as an alternative to traditional tissue biopsies. Read More ›

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. Read More ›

Have you ever asked ChatGPT to create a bio on yourself? Was it spot-on? Somewhat accurate? Total fiction? Read More ›